Adaptive Biotechnologies Corp (ADPT) research
Adaptive Biotechnologies Corp- Sector
- Life Sciences Tools & Services
- Last price
- $28.06
- As of
Adaptive Biotechnologies Corp (ADPT): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-04.
As of . Source: SEC EDGAR filings for ADPT. Method and limitations.
Share the ADPT intelligence card
See ADPT live in the terminal
Track ADPT's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live ADPT terminal, freeActive signals for ADPT
- highCONSENSUS_SELL
3 tracked funds reduced ADPT this 2026Q2, institutional consensus
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 53% of ADPT (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +732% to ADPT (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +253% to ADPT (2026Q2)
- highINSTITUTIONAL_SURGE
D. E. Shaw & Co., Inc. added +135% to ADPT (2026Q2)
FREE, NO ACCOUNT
Every signal on ADPT, as it fires
You are seeing 5 of 20 signals recorded on ADPT since 2026-08-03.
The five above landed across 2 days. The other 15 were recorded on 2 other days. 18 of the 20 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in ADPT (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| VIKING GLOBAL INVESTORS LPCUSIP 00650F109 · 2026Q2 | $643.4M | 1.83% | , |
| D. E. Shaw & Co., Inc.CUSIP 00650F109 · 2026Q2 | $99.2M | 0.05% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 00650F109 · 2026Q2 | $10.8M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 00650F109 · 2026Q2 | $6.5M | 0.01% | , |
| CITADEL ADVISORS LLCCUSIP 00650F109 · 2026Q2 | $3.9M | 0.00% | , |
| Bridgewater Associates, LPCUSIP 00650F109 · 2026Q2 | $860K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ADPT
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
ADPT against its peers
ADPT's operating margin of -20.6% ranks in the 35th percentile of 23 Life Sciences Tools & Services sub-industry peers, fiscal periods ending between 2025-10-31 and 2026-06-30.
| Metric | ADPT | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 277M USD | 1.2B USD | 37 | 25 |
| Gross margin | n/a | 59.1% | n/a | 13 |
| Operating margin | -20.6% | -3.8% | 35 | 23 |
| Net margin | -21.5% | -3.6% | 37 | 25 |
| Return on equity | -27.2% | -5.0% | 26 | 24 |
| P / E | n/a | 43.8x | n/a | 11 |
Peers (25): ABCL, SHC, BRKR, RGEN, FTRE, TXG, AVTR, TEM, TECH, CRL, MEDP, MRVI, MLAB, CTKB, OABI, MTD, DNA, ILMN, WAT, PACB, A, IQV, CDXS, DHR, MXCT. Fiscal periods ending between 2025-10-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (ADPT: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more ADPT signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to ADPTand get the insider, 13F, options, and confluence read in one view.